-+ 0.00%
-+ 0.00%
-+ 0.00%
Cube Pharmaceutical announced that the company recently received the “Notice of Acceptance” of the marketing application for sodium dimercaptopropionate raw materials issued by the State Drug Administration, registration number Y20260000930. The variety has entered the registration review stage. This application is a chemical raw material used to replicate domestically marketed drugs. As of the announcement date, 3 domestic pharmaceutical products based on this API have been approved; in addition to the company, 1 company with this API registration status is “A”. The acceptance of the marketing application for this API will not have a significant impact on the company's recent performance.
Share
Listen to the news
Cube Pharmaceutical announced that the company recently received the “Notice of Acceptance” of the marketing application for sodium dimercaptopropionate raw materials issued by the State Drug Administration, registration number Y20260000930. The variety has entered the registration review stage. This application is a chemical raw material used to replicate domestically marketed drugs. As of the announcement date, 3 domestic pharmaceutical products based on this API have been approved; in addition to the company, 1 company with this API registration status is “A”. The acceptance of the marketing application for this API will not have a significant impact on the company's recent performance.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending